Clinical Research Directory
Browse clinical research sites, groups, and studies.
Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant
Sponsor: University Health Network, Toronto
Summary
The goal of this clinical trial is to learn if locoregional therapy and immunotherapy can be used together to help patients with hepatocellular carcinoma (HCC) and macrovascular invasion achieve liver transplantation. The main questions it aims to answer are: * How many patients will achieve transplant with this treatment strategy? * What will the 5-year survival and recurrence-free survival rates be for these patients? Participants will: * Undergo a biopsy of the tumor. * Receive locoregional therapy (SBRT or Y90) followed by immunotherapy (atezolizumab and bevacizumab) 2 to 6 weeks later, for a maximum of 9 months. * Be referred for a liver transplant and undergo the procedure if deemed eligible and safe. * If applicable, be followed for five years post-transplant with regular data collection.
Official title: Downstaging of Hepatocellular Carcinoma with Macrovascular Invasion by Radiotherapy (SBRT or Y90) and Atezolizumab Plus Bevacizumab Followed by Liver Transplantation - a Prospective Trial
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2024-12
Completion Date
2034-06
Last Updated
2024-12-16
Healthy Volunteers
No
Interventions
Atezolizumab & Bevacizumab
Atezolizumab \& Bevacizumab will be initiated as part of the study, as per standard treatment protocol. Administration of Atezolizumab and Bevacizumab will be performed according to SOC in approx. 21-days intervals. Clinical follow up during treatment will be done as per SOC in medical and surgical oncology clinics at UHN.
Yttrium-90 (Y-90)
Storage, administration and treatment of Y90-RE will be done according to established treatment protocols and standard of care at UHN.
Stereotactic body radiotherapy (SBRT)
Dose and administration frequency of SBRT will be done as per current standards for treating HCC at UHN.
Locations (2)
London Health Sciences Centre
London, Ontario, Canada
Toronto General Hospital
Toronto, Ontario, Canada